20 April 2020 – Year-end Trading update: Revenues increase 86%

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Year-end Trading update: Revenues increase 86%

Manchester, UK – 20 April 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the year ended 31 March 2020.

Revenues for the year ended 31 March 2020 were £16.6m (2019: £8.9m), up 86% compared to the previous year, and does not include £0.4m of orders for March that fell into the new financial year due to COVID-19 transport restrictions. The revenue increase reflects organic growth of approximately 36%; 11 months contribution from Elucigene Diagnostics, acquired on 26 April 2019; and three weeks’ contribution from the Company’s French NIPT distribution business, acquired on 10 March 2020.

Revenues by region
The strong growth across all regional segments shown below demonstrates the Company’s diversified geographic base. Despite the disruptions caused by the spread of COVID-19, our customers in Europe are continuing to operate as normal, albeit with some slight timing delays if and where there are localised staffing or logistics issues. The integration of the French distribution business is also progressing to plan.

Our core South East Asian markets have so far been very successful in containing the virus and avoiding restrictive practices which might have otherwise inhibited our business there. Travel disruption has had an impact on our launch in the US, where we do not have local teams in place yet, and whilst we are recording our first revenues in this key market, we do expect further orders to be fulfilled in the new financial year.

Regional segments

Year ended

30 March 2020


Year ended

30 March 2019



















Revenues by product

Global sales of non-invasive prenatal testing (NIPT) products and services grew at 29% and this is whilst UK and Europe customers wait to transition to our Illumina-based IONA® test, for which we are awaiting regulatory approval during the first quarter of the new financial year. Preparations for the product launch are well advanced and will commence as soon as regulatory approval is obtained and COVID-19 restrictions permit.

During the year to 31 March 2020 we have successfully broadened our portfolio beyond NIPT with 22% of sales now derived from reproductive health products and 17% derived from the Company’s rapidly growing Oncology & Research Services activities in Asia.

Product segments

Year ended

31 March 2020


Year ended

31 March 2019







Reproductive Health




Oncology & Research services









Whilst the impact of COVID-19 in the final quarter was a major challenge the Company still delivered a strong end to the year. Yourgene has in place robust systems to continue to operate efficiently and to provide customers with world-leading molecular diagnostic solutions and services. In addition, as announced on 25 March 2020, the Company signed a contract manufacturing agreement with Novacyt S.A. (“Novacyt”) to support the production of COVID-19 diagnostic tests developed by Primerdesign, Novacyt’s molecular diagnostics division. The contribution from this partnership has started to crystallise in the new financial year with our first shipments now successfully completed. 

Lyn Rees, Chief Executive Officer of Yourgene, commented:

“I am delighted with the performance of our business over the year, both in terms of the organic growth and through contributions from acquisitions. Despite the COVID-19 crisis we continue to execute on our strategy of broadening our product mix and international reach, and we are proud to be supporting the global manufacturing efforts for COVID-19 diagnostic tests from our state-of-the-art facilities in Manchester. The Group remains well funded to achieve its objectives and we are confident that our business remains robust going into the new financial year.  In our view the challenging global situation has put into focus more than ever the need for reliable and accurate diagnostic testing and Yourgene is well positioned to make a significant contribution.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122


Cairn Financial Advisers LLP (NOMAD)

Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

Stifel Nicolaus Europe Limited (Sole Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.